Back to Authors

Brenes-Salazar, Jorge

Mayo Clinic

Mayo Clinic

Citations 2

Cardiovascular Manifestations of COVID-19
Nandy, Sneha , Wan, Siu-Hin, Brenes-Salazar, Jorge, Nandy, Sneha , Wan, Siu-Hin, Brenes-Salazar, Jorge

Current Cardiology Reviews | November 4, 2020 | Volume: 17 | Issue: 4 | Pages: No page available

10.2174/1573403x16999201102213827 Get It

Abstract: Coronavirus disease 2019 (COVID-19) first emerged in a group of patients who presented with severe pneumonia in Wuhan, China, in December 2019. A novel virus, now called SARSCoV- 2 (Severe Acute Respiratory Syndrome Coronavirus-2), was isolated from lower respiratory tract samples. The current outbreak of infection has spread to over 100 countries and killed more than 340,000 people as of 25th May, 2020. The predominant clinical manifestation of COVID-19 is a respiratory disease- ranging from mild flu-like symptoms to fulminant pneumonia and Acute Respiratory Distress Syndrome (ARDS). Patients with pre-existing cardiovascular risk factors are considered more susceptible to the virus, and these conditions are often worsened by the infection. Furthermore, COVID-19 infection has led to de novo cardiac complications, like acute myocardial injury and arrhythmias. In this review, we have focused on the cardiovascular manifestations of COVID-19 infection that have been reported in the literature so far. We have also outlined the effect of pre-existing cardiovascular disease as well as risk factors on the clinical course and outcomes of COVID-19 infection.
Association between the Charlson comorbidity index and outcomes after implantable cardioverter defibrillator generator replacement
Amin, Mustapha M., Witt, Chance M. , Waks, Jonathan W. , Mehta, Ramila A. , Friedman, Paul A. , Kramer, Daniel B. , Buxton, Alfred E. , Mulpuru, Siva K. , Hodge, David O. , Frey, Rebecca J., Frederick, Nicolette K., Cha, Yong‐Mei , Brenes-Salazar, Jorge A., Madhavan, Malini , Brenes-Salazar, Jorge

Pacing and Clinical Electrophysiology | July 29, 2019 | Volume: 42 | Issue: 9 | Pages: 1236-1242

10.1111/pace.13762 Get It

AbstractBackgroundRecipients of implantable cardioverter defibrillator (ICD) generator replacement with multiple medical comorbidities may be at higher risk of adverse outcomes that attenuate the benefit of ICD replacement. The aim of this investigation was to study the association between the Charlson comorbidity index (CCI) and outcomes after ICD generator replacement.MethodsAll patients undergoing first ICD generator replacement at Mayo Clinic, Rochester and Beth Israel Deaconess Medical Center, Boston between 2001 and 2011 were identified. Outcomes included: (a) all‐cause mortality, (b) appropriate ICD therapy, and (c) death prior to appropriate therapy. Multivariable Cox regression analysis was performed to assess association between CCI and outcomes.ResultsWe identified 1421 patients with mean age of 69.6 ± 12.1 years, 81% male and median (range) CCI of 3 (0‐18). During a mean follow‐up of 3.9 ± 3 years, 52% of patients died, 30.6% experienced an appropriate therapy, and 23.6% died without experiencing an appropriate therapy. In multivariable analysis, higher CCI score was associated with increased all‐cause mortality (Hazard ratio, HR 1.10 [1.06‐1.13] per 1 point increase in CCI, P < .001), death without prior appropriate therapy (HR 1.11 [1.07‐1.15], P < .0001), but not associated with appropriate therapy (HR 1.01 [0.97‐1.05], P = .53). Patients with CCI ≥5 had an annual risk of death of 12.2% compared to 8.7% annual rate of appropriate therapy.ConclusionsCCI is predictive of mortality following ICD generator replacement. The benefit of ICD replacement in patients with CCI score ≥5 should be investigated in prospective studies.